Skip to main content

Abacavir / dolutegravir / lamivudine News

ViiV Healthcare Announces US FDA Approval of Triumeq PD, the First Dispersible Single Tablet Regimen Containing Dolutegravir, a Once-Daily Treatment for Children Living with HIV

London, 30 March 2022 – ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has a...

FDA Medwatch Alert: Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects

ISSUE: Serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir used to treat human immunodeficiency...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

HIV Infection

Related drug support groups

Triumeq

Abacavir / dolutegravir / lamivudine patient information at Drugs.com